Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetes

被引:55
作者
Jaffa, Ayad A. [1 ,4 ]
Usinger, William R. [4 ]
McHenry, M. Brent [2 ,3 ]
Jaffa, Miran A. [2 ,3 ]
Lipstiz, Stuart R. [2 ,3 ]
Lackland, Daniel [2 ,3 ]
Lopes-Virella, Maria [1 ]
Luttrell, Louis M. [1 ]
Wilson, Peter W. F. [1 ]
机构
[1] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA
[2] Med Univ S Carolina, Div Endocrinol Diabet Genet Med, Charleston, SC 29425 USA
[3] Med Univ S Carolina, Dept Bioinformat Biostat & Epidemiol, Charleston, SC 29425 USA
[4] FibroGen Inc, San Francisco, CA USA
关键词
D O I
10.1210/jc.2007-2544
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: We explored the relevance and significance of connective tissue growth factor (CTGF) as a determinant of renal and vascular complications among type 1 diabetic patients. Methods and Results: We measured the circulating and urinary levels of CTGF and CTGFN fragment in 1050 subjects with type 1 diabetes from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study cohort. We found that hypertensive diabetic subjects have significantly higher levels of plasma log CTGF N fragment relative to normotensive subjects (P < 0.0005). Multiple regression analysis showed a positive and independent association between CTGF N fragment levels and log albumin excretion rate (P = 0.0001). In categorical analysis, patients with macroalbuminuria had higher levels of CTGF N fragment than diabetic subjects with or without microalbuminuria (P < 0.0001). Univariate and multiple regression analyses demonstrated an independent and significant association of log CTGF N fragment with the common and internal carotid intima-media thickness. The relative risk for increased carotid intima-media thickness was higher in patients with concomitantly elevated plasma CTGF N fragment and macroalbuminuria relative to patients with normal plasma CTGF N fragment and normal albuminuria (relative risk = 4.76; 95% confidence interval, 2.21-10.25; P < 0.0001). Conclusion: These findings demonstrate that plasma CTGF is a risk marker of diabetic renal and vascular disease.
引用
收藏
页码:1893 / 1900
页数:8
相关论文
共 27 条
[1]   Microalbuminuria in diabetes: focus on cardiovascular and renal risk reduction. [J].
Bakris G.L. ;
Sowers J.R. .
Current Diabetes Reports, 2002, 2 (3) :258-262
[2]   THE MODULAR ARCHITECTURE OF A NEW FAMILY OF GROWTH-REGULATORS RELATED TO CONNECTIVE-TISSUE GROWTH-FACTOR [J].
BORK, P .
FEBS LETTERS, 1993, 327 (02) :125-130
[3]  
CHRISTLIEB AR, 1981, DIABETES, V30, P90
[4]  
EDIC Res Grp, 1999, DIABETES, V48, P383
[5]   Pioglitazone inhibits connective tissue growth factor expression in advanced atherosclerotic plaques in low-density lipoprotein receptor-deficient mice [J].
Game, Bryan A. ;
He, Lin ;
Jarido, Veronica ;
Nareika, Alena ;
Jaffa, Ayad A. ;
Lopes-Virella, Maria F. ;
Huang, Yan .
ATHEROSCLEROSIS, 2007, 192 (01) :85-91
[6]  
Genuth S, 1999, DIABETES CARE, V22, P99
[7]   Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy [J].
Gilbert, RE ;
Akdeniz, A ;
Weitz, S ;
Usinger, WR ;
Molineaux, C ;
Jones, SE ;
Langham, RG ;
Jerums, G .
DIABETES CARE, 2003, 26 (09) :2632-2636
[8]   TGF-β and CTGF have overlapping and distinct fibrogenic effects on human renal cells [J].
Gore-Hyer, E ;
Shegogue, D ;
Markiewicz, M ;
Lo, SL ;
Hazen-Martin, D ;
Greene, EL ;
Grotendorst, G ;
Trojanowska, M .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2002, 283 (04) :F707-F716
[9]   Individual domains of connective tissue growth factor regulate fibroblast proliferation and myofibroblast differentiation [J].
Grotendorst, GR ;
Duncan, MR .
FASEB JOURNAL, 2005, 19 (07) :729-738
[10]   Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165 [J].
Hashimoto, G ;
Inoki, I ;
Fujii, Y ;
Aoki, T ;
Ikeda, E ;
Okada, Y .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (39) :36288-36295